Advanced

SATB1 is an independent prognostic factor in radically resected upper gastrointestinal tract adenocarcinoma.

Hedner, Charlotta LU ; Gaber, Alexander LU ; Korkocic, Dejan; Nodin, Björn LU ; Uhlén, Mathias; Kuteeva, Eugenia; Johannesson, Henrik; Jirström, Karin LU and Eberhard, Jakob LU (2014) In Virchows Archiv: an international journal of pathology 465(6). p.649-659
Abstract
Gastric cancer is the second most common cause of cancer-related death worldwide, and the incidence of esophageal adenocarcinoma is rising. While some progress has been made in treatment strategies, overall survival remains very poor for patients with adenocarcinoma in the upper gastrointestinal tract. Special AT-rich sequence binding protein 1 (SATB1) is a global genome organizer that has been demonstrated to promote aggressive tumor behavior in several different types of cancer, including gastric cancer. The prognostic value of SATB1 expression in esophageal cancer has, however, not yet been described. In this study, expression of SATB1 was examined by immunohistochemistry on tissue microarrays prepared from tissue samples from 175... (More)
Gastric cancer is the second most common cause of cancer-related death worldwide, and the incidence of esophageal adenocarcinoma is rising. While some progress has been made in treatment strategies, overall survival remains very poor for patients with adenocarcinoma in the upper gastrointestinal tract. Special AT-rich sequence binding protein 1 (SATB1) is a global genome organizer that has been demonstrated to promote aggressive tumor behavior in several different types of cancer, including gastric cancer. The prognostic value of SATB1 expression in esophageal cancer has, however, not yet been described. In this study, expression of SATB1 was examined by immunohistochemistry on tissue microarrays prepared from tissue samples from 175 patients with adenocarcinoma of the esophagus, cardia, or stomach and containing normal tissue, intestinal metaplasia, primary tumors, and metastases. A well-validated antibody was used. We found SATB1 to be an independent prognostic factor in patients with a radically resected tumor, correlating with shorter overall survival as well as with shorter recurrence-free survival. SATB1 expression was also found to be significantly lower in primary tumors associated with intestinal metaplasia than those without intestinal metaplasia. This observation is of potential biological interest as it has been proposed that intestinal metaplasia-associated tumors constitute a less aggressive phenotype. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Virchows Archiv: an international journal of pathology
volume
465
issue
6
pages
649 - 659
publisher
Springer
external identifiers
  • pmid:25326863
  • wos:000345598300005
  • scopus:84914151513
ISSN
1432-2307
DOI
10.1007/s00428-014-1667-6
language
English
LU publication?
yes
id
2aba48a1-cbf3-47f1-8d0b-b91d504b04ff (old id 4733782)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/25326863?dopt=Abstract
date added to LUP
2014-11-09 23:29:33
date last changed
2017-11-12 03:07:03
@article{2aba48a1-cbf3-47f1-8d0b-b91d504b04ff,
  abstract     = {Gastric cancer is the second most common cause of cancer-related death worldwide, and the incidence of esophageal adenocarcinoma is rising. While some progress has been made in treatment strategies, overall survival remains very poor for patients with adenocarcinoma in the upper gastrointestinal tract. Special AT-rich sequence binding protein 1 (SATB1) is a global genome organizer that has been demonstrated to promote aggressive tumor behavior in several different types of cancer, including gastric cancer. The prognostic value of SATB1 expression in esophageal cancer has, however, not yet been described. In this study, expression of SATB1 was examined by immunohistochemistry on tissue microarrays prepared from tissue samples from 175 patients with adenocarcinoma of the esophagus, cardia, or stomach and containing normal tissue, intestinal metaplasia, primary tumors, and metastases. A well-validated antibody was used. We found SATB1 to be an independent prognostic factor in patients with a radically resected tumor, correlating with shorter overall survival as well as with shorter recurrence-free survival. SATB1 expression was also found to be significantly lower in primary tumors associated with intestinal metaplasia than those without intestinal metaplasia. This observation is of potential biological interest as it has been proposed that intestinal metaplasia-associated tumors constitute a less aggressive phenotype.},
  author       = {Hedner, Charlotta and Gaber, Alexander and Korkocic, Dejan and Nodin, Björn and Uhlén, Mathias and Kuteeva, Eugenia and Johannesson, Henrik and Jirström, Karin and Eberhard, Jakob},
  issn         = {1432-2307},
  language     = {eng},
  number       = {6},
  pages        = {649--659},
  publisher    = {Springer},
  series       = {Virchows Archiv:  an international journal of pathology},
  title        = {SATB1 is an independent prognostic factor in radically resected upper gastrointestinal tract adenocarcinoma.},
  url          = {http://dx.doi.org/10.1007/s00428-014-1667-6},
  volume       = {465},
  year         = {2014},
}